Focused On-demand Library for Centrosomal protein of 135 kDa

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q66GS9

UPID:

CP135_HUMAN

Alternative names:

Centrosomal protein 4

Alternative UPACC:

Q66GS9; B2RMY0; O75130; Q58F25; Q9H8H7

Background:

Centrosomal protein of 135 kDa, also known as Centrosomal protein 4, plays a pivotal role in centriole biogenesis. It functions as a scaffolding protein, essential for the recruitment of centriole satellite proteins and centriole-centriole cohesion during interphase. Its involvement in the targeting of proteins such as PCM1, SSX2IP, CEP290, and the recruitment of WRAP73 and CEP295 to centrioles underscores its critical role in cell division.

Therapeutic significance:

The protein's link to Microcephaly 8, a condition characterized by significantly reduced brain size and mental retardation, highlights its potential as a target for therapeutic intervention. Understanding the role of Centrosomal protein of 135 kDa could open doors to potential therapeutic strategies.